Novinrooz Aytak, Zahraei Salehi Taghi, Firouzi Roya, Arabshahi Sina, Derakhshandeh Abdollah
Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
PLoS One. 2017 Mar 15;12(3):e0173761. doi: 10.1371/journal.pone.0173761. eCollection 2017.
E. coli O157:H7, one of the major EHEC serotypes, is capable of developing bloody diarrhea, hemorrhagic colitis (HC), and fatal hemolytic uremic syndrome (HUS) and is accompanied by high annual economic loss worldwide. Due to the increased risk of HC and HUS development following antibiotic therapy, the prevention of infections caused by this pathogen is considered to be one of the most effective ways of avoiding the consequences of this infection. The main aim of the present study was to design, express, and purify a novel chimeric protein to develope human vaccine candidate against E. coli O157:H7 containing loop 2-4 of E. coli O157:H7, outer membrane protein A (OmpA), and B subunit of E. coli heat labile enterotoxin (LTB) which are connected by a flexible peptide linker. Several online databases and bioinformatics software were utilized to choose the peptide linker among 537 analyzed linkers, design the chimeric protein, and optimize the codon of the relative gene encoding this protein. Subsequently, the recombinant gene encoding OmpA-LTB was synthesized and cloned into pET-24a (+) expression vector and transferred to E. coli BL21(DE3) cells. The expression of OmpA-LTB chimeric protein was then carried out by induction of cultured E. coli Bl21 (DE3) cells with 1mM isopropyl-β-D-thiogalactopyranoside (IPTG). The purification of OmpA-LTB was then performed by nickel affinity chromatography. Expression and purification were analyzed by sodium dodecyl sulphate poly acrylamide gel electrophoresis. Moreover, the identity of the expressed protein was analyzed by western blotting. SDS-PAGE and western immunoblotting confirmed the successful expression of a 27 KDa recombinant protein after 24 hours at 37°C post-IPTG induction. OmpA-LTB was then successfully purified, using nickel affinity chromatography under denaturing conditions. The yield of purification was 12 mg per liter of culture media. Ultimately, we constructed the successful design and efficient expression and purification of OmpA-LTB divalent under the above-mentioned conditions.
大肠杆菌O157:H7是主要的肠出血性大肠杆菌血清型之一,可引发血性腹泻、出血性结肠炎(HC)和致命的溶血尿毒综合征(HUS),并在全球范围内造成高昂的年度经济损失。由于抗生素治疗后发生HC和HUS的风险增加,预防这种病原体引起的感染被认为是避免这种感染后果的最有效方法之一。本研究的主要目的是设计、表达并纯化一种新型嵌合蛋白,以开发针对大肠杆菌O157:H7的人用候选疫苗,该嵌合蛋白包含大肠杆菌O157:H7的环2-4、外膜蛋白A(OmpA)和大肠杆菌热不稳定肠毒素(LTB)的B亚基,它们通过柔性肽接头连接。利用多个在线数据库和生物信息学软件,在537个分析的接头中选择肽接头,设计嵌合蛋白,并优化编码该蛋白的相关基因的密码子。随后,合成编码OmpA-LTB的重组基因,并克隆到pET-24a(+)表达载体中,然后转移到大肠杆菌BL21(DE3)细胞中。然后通过用1mM异丙基-β-D-硫代半乳糖苷(IPTG)诱导培养的大肠杆菌Bl21(DE3)细胞来进行OmpA-LTB嵌合蛋白的表达。然后通过镍亲和层析对OmpA-LTB进行纯化。通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳分析表达和纯化情况。此外,通过蛋白质印迹分析表达蛋白的同一性。SDS-PAGE和蛋白质免疫印迹证实,在IPTG诱导后于37°C培养24小时后成功表达了一种27 kDa的重组蛋白。然后在变性条件下使用镍亲和层析成功纯化了OmpA-LTB。纯化产量为每升培养基12 mg。最终,我们在上述条件下成功构建并高效表达和纯化了OmpA-LTB二价体。